Search research articles
Contact Us
Filters
Showing results (541-550 of 661) with videos related to
Page
of 67
Sort By:
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Shun Lu, Jie Wang, Yan Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
The Lancet. Oncology
|
June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
Ziming Li, Jie Hu, Jianhua Chen, et al.
Translational Lung Cancer Research
|
September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options
Jiu-Wei Cui, Qing Zhou, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer
Hai-Yan Tu, Chun Chen, Chang Chen, et al.
Plos One
|
July 15, 2015
TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR
Qian Zhang, Jing Wang, Fang Deng, et al.
JTO Clinical and Research Reports
|
October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study
Xinghao Ai, Qiming Wang, Ying Cheng, et al.
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 67
Search research articles
Search
Showing results (541-550 of 661) with videos related to
Sort By:
Page
of 67
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 25, 2021
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Shun Lu, Jie Wang, Yan Yu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 8, 2025
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Mark M Awad, Patrick M Forde, Nicolas Girard, et al.
The Lancet. Oncology
|
June 15, 2026
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
Ziming Li, Jie Hu, Jianhua Chen, et al.
Translational Lung Cancer Research
|
September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment options
Jiu-Wei Cui, Qing Zhou, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancer
Hai-Yan Tu, Chun Chen, Chang Chen, et al.
Plos One
|
July 15, 2015
TqPCR: A Touchdown qPCR Assay with Significantly Improved Detection Sensitivity and Amplification Efficiency of SYBR Green qPCR
Qian Zhang, Jing Wang, Fang Deng, et al.
JTO Clinical and Research Reports
|
October 11, 2022
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring <i>MET</i> Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xingya Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 15, 2021
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study
Xinghao Ai, Qiming Wang, Ying Cheng, et al.
The New England Journal of Medicine
|
June 5, 2023
Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
Masahiro Tsuboi, Roy S Herbst, Thomas John, et al.
Page
of 67